Numerous phase III studies have shown that EGFR TKIs such as gefitinib or erlotinib have strong anti-tumor activity and increase survival in patients with NSCLC harboring activating EGFR mutation not only in second and third line [3], [4], [5], but also in first line [2], [6], [7] and maintenance treatment [8], [9], [10]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.